LLY
股票Eli Lilly and Co
- 总部
- US
- 行业
- 制药
- 发行时间
- 1985-01-13
- 流通股
- 942M
区间表现
2 小时前关键指标
2 小时前- 市值
- $1.02T
- 企业价值
- $1.05T
- 市盈率 (TTM)
- 40.16
- 预期市盈率
- 27.51
- 市盈率 (年)
- 49.19
- PEG
- 1.37
- 市净率
- 38.29
- 市销率 (TTM)
- 14.05
- 市销率 (年)
- 15.58
- EV / EBITDA
- 31.38×
- EV / 营收
- 14.58×
- 每股收益 (TTM)
- $28.15
- 每股收益 (年)
- $22.95
- 基本每股收益 (TTM)
- $28.15
- 每股净资产
- $28.09
- 毛利率
- 82.83%
- 营业利润率
- 43.63%
- 净利率
- 34.99%
- 净资产收益率 (ROE)
- 101.31%
- 总资产收益率 (ROA)
- 22.73%
- 投资回报率 (ROI)
- 37.71%
- 每股 EBITDA
- $37.37
- 每股营收 (TTM)
- $80.64
- 营收增长 (TTM YoY)
- +47.44%
- 营收增长 (季 YoY)
- +55.55%
- EPS 增长 (TTM YoY)
- +128.83%
- 股息率 (预期)
- 0.64%
- 股息率 (TTM)
- 0.55%
- 每股股息 (TTM)
- $5.91
- 派息率
- 22.10%
- 流动比率
- 1.58
- 速动比率
- 0.78
- 负债权益比
- 1.60
- 长期负债权益比
- 1.54
- Beta
- 0.52
- 波动率 (3M)
- 37.57%
分析师评级
2 小时前财报
2 小时前相关新闻
2 小时前- Yahoo·4 天前companySupreme Court Verdict Tests Eli Lilly Valuation And Legal Risk Outlook
United States Supreme Court upholds a $220 million Medicaid fraud verdict against Eli Lilly under the False Claims Act. Decision stems from a whistleblower case and concludes a 12 year legal dispute. Ruling is described as the first jury verdict against a pharmaceutical company under this statute. Eli Lilly, NYSE: LLY, now has a material legal setback sitting alongside a large market valuation, with the stock recently trading around $1,126.80. The company has very large multi year share...
- Yahoo·4 天前companyEli Lilly (LLY): Top Healthcare Stock Pick of Claude AI
We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Eli Lilly and Company (NYSE:LLY) ranks #2 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 137 Eli Lilly and Company (NYSE:LLY) is among the top stock picks of the Claude […]
- CNBC·4 天前companyPortal Innovations' Flavin on M&A activity in the pharma space
John Flavin, Portal Innovations, joins 'Fast Money' to talk pharma M&A activities.
- Yahoo·4 天前companyLLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
- Yahoo·4 天前companyLilly Reopens Zepbound Access For 10 Million US Patients
CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.
- Yahoo·4 天前companyHealthcare ETFs to Buy as Eli Lily Steps Into Vaccine Market With $4B Bet
LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.
- Yahoo·4 天前companyStock Market News for May 29, 2026
Wall Street closed higher on Thursday, driven by tech and healthcare stocks.
- Yahoo·4 天前companyJim Cramer on Eli Lilly: “Brilliant Management”
Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer discussed on Mad Money, highlighting several companies with market caps over a trillion dollars. Cramer highlighted the company’s new cholesterol drug’s Phase 3 trial, as he commented: Finally, the 11th largest US company, holy cow…. smaller than Micron but still just over 1 trillion, […]
